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A diverse set of oligomeric class II MHC-peptide complexes for
probing T-cell receptor interactions
Jennifer R Cochran and Lawrence J Stern
Background: T-cells are activated by engagement of their clonotypic cell surface
receptors with peptide complexes of major histocompatibility complex (MHC)
proteins, in a poorly understood process that involves receptor clustering on the
membrane surface. Few tools are available to study the molecular mechanisms
responsible for initiation of activation processes in T-cells.
Results: A topologically diverse set of oligomers of the human MHC protein
HLA-DR1, varying in size from dimers to tetramers, was produced by varying the
location of an introduced cysteine residue and the number and spacing of
sulfhydryl-reactive groups carried on novel and commercially available cross-
linking reagents. Fluorescent probes incorporated into the cross-linking reagents
facilitated measurement of oligomer binding to the T-cell surface. Oligomeric
MHC-peptide complexes, including a variety of MHC dimers, trimers and
tetramers, bound to T-cells and initiated T-cell activation processes in an antigen-
speci¢c manner.
Conclusion: T-cell receptor dimerization on the cell surface is suf¢cient to initiate
intracellular signaling processes, as a variety of MHC-peptide dimers differing in
intramolecular spacing and orientation were each able to trigger early T-cell
activation events. The relative binding af¢nities within a homologous series of
MHC-peptide oligomers suggest that T-cell receptors may rearrange in the plane
of the membrane concurrent with oligomer binding.
Department of Chemistry, Massachusetts Institute of
Technology, Cambridge, MA 02139, USA
Correspondence: Lawrence J Stern
E-mail: stern@mit.edu
Keywords: Major histocompatibility complex;
Multivalent binding; Oligomer; Signal transduction;
T-lymphocyte
Received: 18 April 2000
Revisions requested: 2 June 2000
Revisions received: 19 June 2000
Accepted: 29 June 2000
Published: 1 August 2000
Chemistry & Biology 2000, 7:683^696
1074-5521 / 00 / $ ^ see front matter
ß 2000 Elsevier Science Ltd. All rights reserved.
PII: S 1 0 7 4 - 5 5 2 1 ( 0 0 ) 0 0 0 1 9 - 3
Introduction
Major histocompatibility complex (MHC) proteins are cell
surface KL heterodimeric glycoproteins (molecular weight
(MW) V60 kDa) that bind peptides within the cell and
present them at the cell surface for recognition by antigen-
speci¢c T-cells [1,2]. MHC-peptide complexes on the sur-
face of antigen-presenting cells are bound by receptors on
the surface of T-cells, in a process that leads to activation
of T-cell effector functions and initiation of immune re-
sponses [3]. T-cell receptors (TCRs) are multi-subunit
membrane glycoproteins that include clonally expressed
antigen-binding KL subunits (MWV60 kDa) [4]. Three-
dimensional structures have been determined by X-ray
crystallography for the extracellular domains of many class
I and class II MHC proteins in complex with de¢ned pep-
tides [5], and for the antigen-binding domains of several
TCRs and TCR/MHC co-complexes [6].
The molecular events occurring at the interface between a
T-cell and an antigen-presenting cell that lead to MHC-
stimulated T-cell activation are unknown and of consider-
able interest. Oligomerization of TCR molecules at the T-
cell surface is believed to be the proximal stimulus for
triggering T-cell cytoplasmic signaling cascades [7], but
molecular characteristics of the putative TCR activating
oligomer are not known. Alternative mechanisms involving
MHC-induced TCR conformational or allosteric changes
also have been proposed [8^11]. There are many factors
complicating investigation of MHC/TCR interactions. The
association of MHC-peptide complexes with TCR is a
weak interaction, with af¢nities (Kd) for soluble extracellu-
lar domains typically ranging from 1036 to 1034 M [12,13].
MHC and TCR proteins are anchored in different cell
membranes that must be juxtaposed during activation, in
a process that can include other components from both
cells [14]. MHC proteins on the surface of antigen-present-
ing cells typically will be occupied with a large number of
different peptides, although recombinant sources of solu-
ble MHC complexes with de¢ned peptides are available
[15^17]. Finally, the antigen-binding TCR KL subunits
contain very short cytoplasmic domains not believed to
participate in T-cell signaling, and activation signals are
transmitted into the T-cell through association with TCR
CD3QNO and j2 subunits, which possess multiple signaling
motifs [18].
Soluble MHC-peptide complexes have been used to in-
vestigate the molecular requirements for activation of T-
cells. In this approach, arrays of puri¢ed MHC-peptide
complexes are used to mimic the physiological effect of
an antigen-presenting cell (Figure 1). Experiments with
dimeric chimeras of MHC-peptide complexes fused to
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antibody Fc portions [19^21], antibody-linked MHC
dimers [22], and a series of streptavidin-based oligomers
of biotinylated MHC-peptide complexes [23], have yielded
con£icting measures of the minimum MHC oligomer size
required for activation of T-cells. One constraint of these
approaches is that the intramolecular valency, orientation
and spacing are controlled by the antibody or streptavidin
moieties used to form the oligomers. Dif¢culties in prepar-
ing homogenous oligomer species further limit the appli-
cations of these reagents in probing MHC/TCR interac-
tions.
We have developed a series of novel, chemically-de¢ned,
oligomeric complexes of the human MHC class II protein
HLA-DR1 for investigation of the molecular mechanism of
T-cell activation. MHC-peptide complexes were modi¢ed
to carry an introduced cysteine residue at the C-terminus
of the K subunit or the L subunit of the MHC molecule,
and were oligomerized with cross-linking reagents carrying
two, three or four thiol-speci¢c reactive sites with varying
inter-site spacing and £exibility. Fluorescent labels incor-
porated into the cross-linking reagents allowed detection of
MHC-peptide oligomer binding to T-cells. In contrast to
previous approaches, our strategy permits construction of a
range of novel MHC-peptide oligomers with varying va-
lency, orientation, and topological constraints. These olig-
omers offer a unique set of topologies for the presentation
of peptide to T-cells and for investigation of the effect of
MHC geometry on T-cell signaling.
Results
Cysteine modi¢cations of HLA-DR1
Our oligomerization strategy was based on introduction of
speci¢c cross-links through reactive sulfhydryl groups in-
troduced separately at the C-terminus of the K or L subunit
of HLA-DR1. To generate the shorter Cys-modi¢ed sub-
units Kcys and Lcys, Cys residues were introduced after
residues K182 or L190, at the end of the lower immuno-
globulin domains that support the peptide binding site and
immediately after the last well-ordered residues visible in
the crystal structures [24,25] (Figure 2A,B). To generate
the longer Cys-modi¢ed subunits KLcys and LLcys, Ala-
Cys sequences were introduced individually after the ‘con-
necting peptide’ regions K183^192 or L191^198, just be-
fore the predicted start of the transmembrane portions
(Figure 2A,B). HLA-DR1 has seven other cysteine resi-
dues, forming three disul¢de bonds and one free cysteine.
The HLA-DR1 intramolecular disul¢de bonds (K108^164,
L16^79, L118^174) are buried within the folded protein
and are stable to at least 100 mM dithiothreitol [16]. Con-
trol experiments established that the free cysteine (L30) is
buried underneath the bound peptide and unreactive to
soluble thiol-speci¢c maleimide or pyridyl disul¢de probes
in the folded MHC-peptide complex (JRC, not shown).
The introduced sulfhydryl residues undergo facile reaction
with thiol-speci¢c reagents, allowing speci¢c cross-linking
at the K or L subunit termini.
Folded HLA-DR1 KL complexes carrying the introduced
cysteine residues were produced by dilution of urea-solu-
bilized K and L subunits into denaturant-free buffer in the
presence of antigenic viral peptide (Ha) or control endog-
enous peptide (A2), using a previously described protocol
[16]. Both peptides bind tightly to HLA-DR1 with
KdV10^50 nM [26] and dissociation half-life V100^300
h [27]. Introduction of the cysteine residues did not affect
protein folding, as assayed by reactivity with antibodies
speci¢c for the folded DR1 KL heterodimer (not shown),
or with the ability of the folded complexes to bind peptide,
as determined by resistance to sodium dodecyl sulfate
(SDS)-induced subunit dissociation (Figure 2C). Cys-
teine-modi¢ed MHC-peptide complexes were puri¢ed in
the presence of 5 mM dithiothreitol, which was removed
immediately prior to cross-linking reactions. Using this pro-
cedure, more than 90% of the puri¢ed folded peptide com-
plexes carried an unmodi¢ed, reactive thiol, as determined
using a £uorescent sulfhydryl-reactive probe (see Materials
and methods).
MHC oligomers prepared using commercially available
cross-linking reagents
Homobifunctional cross-linking reagents are readily avail-
able carrying a variety of sulfhydryl-reactive groups such as
pyridyl disul¢des, maleimides and vinyl sulfones. A sam-
pling of commercially available homobifunctional thiol-spe-
ci¢c cross-linking reagents was chosen to test the cross-
linking ef¢ciencies of the cysteine-modi¢ed MHC-peptide
complexes (Figure 3A). Pyridyl disul¢des are very reactive
towards thiols, and unlike the other sulfhydryl-reactive
species the S^S bond that is formed can be reversibly
cleaved with a reducing agent for ease in characterization
or recovery of cross-linked molecules [28]. Maleimides also
are highly reactive to thiols, but hydrolysis of the cross-
linking reagent competes with thiol reaction [29], and the
reaction can be (slowly) reversible. Vinyl sulfones suffer
much less from competing hydrolysis and form stable link-
ages [30], but do not appear to be as reactive towards thiols
as maleimides or pyridyl disul¢des (JRC, not shown).
Figure 1. Arrays of MHC-peptide complexes can act as mimics of
an antigen-presenting cell. T-cells are activated by multivalent
engagement of their receptors [7].
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Dimeric MHC-peptide complexes were prepared with the
free thiol on the long version of the K subunit of HLA-
DR1-Ha (cysLKL) using 1,4-di-[3P-(2P-pyridyldithio)propio-
namido]butane (DPDPB) or 1,6-hexane-bis(vinyl sulfone)
(HBVS) (Figure 3A,B). Cross-linker and protein concentra-
tions in the reaction mixture were varied to obtain opti-
mum cross-linking ef¢ciency. DPDPB cross-linking could
be used to produce dimers with an ef¢ciency of approxi-
mately 60%, while HBVS was less effective, producing
dimers with V15% ef¢ciency, as estimated by SDS^
PAGE and gel ¢ltration chromatography (Figure 3B,C).
Much higher ef¢ciencies of cross-linking (V90%) were
obtained through formation of direct disul¢de bonds be-
tween the introduced thiols, using copper 1,10-phenan-
throline to catalyze the oxidation (Figure 3B,C) [31]. Tri-
meric MHC-peptide complexes were formed with tris-2-
[maleimidoethyl]amine (TMEA), a commercially available
sulfhydryl-reactive trimeric cross-linking reagent (Figure
2A,B). However, the cross-linking yield with this reagent
was extremely low (6 10%), perhaps due to steric hin-
drance between the three cross-linked MHC molecules
(Figure 3B,C).
Oligomerized cysLKL MHC-peptide complexes were puri-
¢ed by gel ¢ltration chromatography (Figure 3C). SDS^
PAGE analysis showed that the puri¢ed cross-linked
MHC-peptide complexes had formed the correct K subunit
(LcysK-LcysK) covalent cross-links and retained their bound
peptide (Figure 3B). The puri¢ed complexes exhibited the
sizes expected for soluble dimeric and trimeric MHC pro-
teins with no tendency to aggregate, as judged by gel
¢ltration chromatography (Figure 3D).
Commercially available cross-linking reagents can be used
to prepare MHC dimers and trimers, but they have several
limitations. These reagents are not £uorescent or otherwise
labeled, and therefore cannot be used in direct binding or
T-cell detection assays. Furthermore, the thiol-reactive ho-
motrimeric cross-linking reagent TMEA exhibits a low
cross-linking ef¢ciency, and a homotetrameric reagent is
not available. Cross-linking reagents that incorporate detec-
tion labels, and are available in a wide range of oligomeric
sizes, would be preferred for high-af¢nity T-cell binding
and to probe the effects of oligomer size on MHC/TCR
interactions. Thus we developed an alternate cross-linking
strategy, based on polypeptides carrying pendant thiol-re-
active groups.
Figure 2. Design and construction of
cysteine-modi¢ed class II MHC proteins.
(A) Diagram of wild type and cysteine-
modi¢ed K and L polypeptide chains of
HLA-DR1. The positions of the signal
sequences (SS), £exible `connecting
peptide' regions (P), transmembrane
domains (TM) and cytoplasmic domains
(C) are indicated on the full length DRK
and DRL genes. Cysteine residues were
introduced individually at the C-terminus of
the extracellular portions of the polypeptide
chains after K182 (Kcys) or L190 (Lcys), or
Ala-Cys sequences were added
individually after the `connecting peptide'
regions at K192 (KLcys) or L198 (LLcys).
Native disul¢de bonds produced upon
folding are indicated by S^S. DRL carries
a free cysteine residue (L30) that is
sequestered in the peptide binding site in
a folded MHC-peptide complex. (B) Ribbon
diagram of HLA-DR1 with K subunit (DRK,
blue), L subunit (DRL, green) and bound
peptide (yellow) from the crystal structure
[25]. Open arrows indicate the termini of
the short constructions Kcys and Lcys. Filled
arrows indicate the termini of the long
constructions KLcys and LLcys. The
connecting peptide regions (red) are poorly
de¢ned by the crystal structure and can
adopt different conformations [25]. (C) Non-
reducing SDS^PAGE (12.5%) of puri¢ed
MHC-peptide complexes of wild type DR1
(KL), and DR1 with the introduced cysteine
residue on the C-terminus of the connecting
peptide region of the K chain (cysLKL) or of
the L chain (KLLcys). The additional cysteine
residues do not affect protein folding or the
ability of the MHC to bind the Ha peptide
antigen, as indicated by the presence of
SDS-resistant KL heterodimer bands
(3boil), that dissociate into K and L chains
upon boiling (+boil). DR1 molecules that
have lost their bound peptide dissociate in
the presence of SDS [15].
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MHC oligomers prepared using novel peptide-based
synthetic cross-linking reagents
For production of a set of £uorescently labeled oligomers
with variable valency, we designed and chemically synthe-
sized peptide-based cross-linking reagents containing a
£uorescent label (£uorescein) and two or more thiol-reac-
tive maleimide groups introduced at lysine residues spaced
along a £exible backbone composed of glycine, serine, and
glutamic acid (Figure 4A). The non-repeating backbone
amino acid sequences were designed to be water-soluble
with little propensity to form an ordered structure, and to
provide suf¢cient length and £exibility to allow pendant
MHC molecules to bind simultaneously to a cell surface.
Maleimide-to-maleimide distances for the cross-linkers, in
extended conformations that would allow pendant MHC
molecules to present peptides in the same plane, are ap-
proximately 45 Aî for the dimeric cross-linker (pep-2), and
50 Aî for the trimeric (pep-3) and tetrameric (pep-4) cross-
linkers, as estimated from molecular models.
Dimeric, trimeric, and tetrameric complexes of HLA-DR1
were formed through reaction of the synthetic cross-linkers
with MHC proteins carrying the introduced cysteine resi-
due on the long version of the L subunit (KLLcys) (Figure
4B). The cross-linking ef¢ciency for the dimeric cross-link-
er pep-2 was comparable to that observed for DPDPB
(V60%) (Figure 4B,C), while the cross-linking ef¢ciency
for the trimeric pep-3 was approximately 35% (Figure
4B,D), signi¢cantly greater than that observed for
TMEA. The tetrameric cross-linker pep-4 was able to cou-
Figure 3. Oligomerization of MHC-peptide
complexes with commercially available
cross-linking reagents. (A) Chemical
structures of the dimeric cross-linking
reagents DPDPB and HBVS, and the
trimeric cross-linker TMEA, carrying a
variety of sulfhydryl-reactive functional
groups. (B) Non-reducing 12.5% SDS^
PAGE of cross-linking reaction mixtures
(rx) and puri¢ed oligomers (pure) of Cys-
modi¢ed HLA-DR1 (cysLKL) coupled with
DPDPB, HBVS, S^S and TMEA. The
position of unreacted monomer (KL), and
cross-linked dimers ((KL)2) and trimer
((KL)3) are indicated. Cross-linked MHC-
peptide dimers exhibit the correct covalent
bond through the K subunits ((K)2), as
shown by stability to boiling in SDS (+boil).
(C) Gel ¢ltration of reaction mixtures of
MHC-peptide oligomers coupled through
the K subunit (cysLKL) demonstrates the
relative coupling ef¢ciencies of the various
cross-linking reagents. Data are
representative of several experiments. (D)
Gel ¢ltration traces of puri¢ed MHC-peptide
complexes exhibit the sizes expected for
monomer (1³), dimers (2³) and TMEA
trimer (3³). The pro¢le for MW standards is
indicated below the oligomer traces in C
and D.
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ple KLLcys with an ef¢ciency of approximately 25% (Figure
4B,E). The cross-linked MHC-peptide complexes were
puri¢ed by gel ¢ltration chromatography (Figure 4C^G).
Puri¢ed oligomeric MHC-peptide complexes exhibited
the expected L subunit covalent cross-links as analyzed
by SDS^PAGE (not shown) and had no tendency to ag-
gregate as judged by gel ¢ltration chromatography (Figure
4H). Tetrameric oligomers were also prepared with the
MHC-peptide complexes carrying cysteine residues on
the shorter version of the L subunit (KLcys) (Figure 4F),
and with MHC-peptide complexes carrying an unmodi¢ed
L subunit and the cysteine introduced on the longer K
subunit (cysLKL) (Figure 4G). Tetramer cross-linking ef¢-
ciencies for these constructions were approximately 40%
and 45%, respectively, somewhat higher than obtained
with KLLcys.
Puri¢ed oligomeric MHC-peptide complexes exhibited in-
creasing apparent MW with increasing oligomer size, in a
roughly linear relationship, as expected for a series of con-
catenated particles (Figure 5A). Oligomers prepared from
MHC-peptide complexes containing the connecting pep-
tide region (KLLcys) exhibited apparent MW larger than the
corresponding oligomers lacking the connecting peptide
(KLcys) (Table 1). The difference was greater than that
predicted from the actual MW increase of the connecting
peptide region (Table 1), suggesting that the connecting
peptide regions of the oligomer are in an extended rather
than compact conformation (the apparent MW is calculated
using a compact, spherical particle model [26]). Hydrody-
namic Stokes radii (Rs), calculated from the apparent MW
(Table 1), indicate that inclusion of the L subunit connect-
ing peptide region causes a small increase in the particle
Figure 4. Oligomerization of MHC-peptide complexes using synthetic £uorescent cross-linking reagents. (A) Chemical structures of
£uorescein-labeled, peptide-based cross-linkers for production of MHC dimers (pep-2), trimers (pep-3) and tetramers (pep-4). All cross-
linkers carry maleimide groups for coupling to cysteine residues introduced into HLA-DR1. (B) 10% SDS^PAGE of cross-linking reactions
(rx) and puri¢ed oligomeric complexes (pure) of Cys-modi¢ed HLA-DR1-Ha coupled through the L subunit (KLLcys). (C^G) Gel ¢ltration
traces of reaction mixtures of (C) KLLcys pep-2³, (D) KLLcys pep-3³, (E) KLLcys pep-4³, (F) KLcys pep-4³ and (G) cysLKL pep-4³. The position
of MW standards is indicated by lines above the traces. (H) Gel ¢ltration traces of puri¢ed MHC oligomers exhibit the sizes expected for
monomer (1³), dimer (pep-2³), trimer (pep-3³), and tetramer (pep-4³). The pro¢le of MW standards is indicated below the oligomer traces.
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radius (0.9^1.2 Aî ), consistent with the addition of eight
amino acid residues.
Relative binding af¢nities were determined using a com-
petitive binding assay, in which puri¢ed oligomeric MHC-
peptide complexes were used to compete for binding to
receptors on the surface of T-cells with tetramers formed
by oligomerization of biotinylated MHC monomers with
phycoerythrin-labeled streptavidin [32]. Half-maximal in-
hibitory concentrations (IC50) varied systematically with
oligomer size, with larger oligomers binding more tightly.
A plot of IC50 versus oligomer size (Figure 5B) revealed a
log-linear dependence that does not cross the origin (log
IC50 =35.6n34.8, R = 0.97). This indicates that each addi-
tional concatenated MHC-peptide unit contributes a sim-
ilar binding energy to the overall oligomer interaction, with
the increment for each monomer signi¢cantly less than that
contributed by binding a single MHC-peptide complex
(see Discussion).
MHC-peptide dimers with varying intramolecular
orientation and topological constraints
The availability of MHC proteins with cysteine residues at
variable positions, along with cross-linkers of variable
Figure 5. Characterization of MHC-peptide
oligomers. (A) Oligomer valency versus
apparent MW (MWapp) determined from
data in Figure 4. (B) Oligomer valency
versus relative T-cell binding af¢nity,
determined by a competitive binding assay.
IC50 values for the competition binding are
plotted against the oligomer valency,
revealing the approximate relationship
log IC50 =35.6n34.8, R = 0.97. Inset, IC50
values and standard deviations. Error bars
represent the standard deviation of IC50
values and MWapp calculated from three
separate experiments.
Table 1
Hydrodynamic behavior of MHC-peptide oligomers.
MHC-peptide Cross-link Valency MWa MWbapp (kDa)
gel ¢ltration
MWapp/MW Rcs (Aî )
KL monomer 1 44 820 41 þ 0.7 0.91 27.2 þ 0.15
KL crystal (calc)d 1 27.1
cysKL S^S 2 89 843 94 þ 1 1.05 34.3 þ 0.14
cysKL pep-2³ 2 91 380 99 þ 1 1.08 34.9 þ 0.07
KLcys S^S 2 89 843 105 þ 1 1.17 35.6 þ 0.12
KLcys pep-2³ 2 91 380 110 þ 0.1 1.20 36.1 þ 0.03
cysLKL S^S 2 92 118 112 þ 0.9 1.22 36.4 þ 0.14
cysLKL pep-2³ 2 93 654 119 þ 0.5 1.27 37.1 þ 0.07
KLLcys S^S 2 91 733 116 þ 1 1.26 36.8 þ 0.06
KLLcys pep-2³ 2 93 270 119 þ 0.8 1.28 37.1 þ 0.07
(KL)2 crystal (calc)d 2 34.2
KLcys pep-3³ 3 137 460 192 þ 4 1.40 43.5 þ 0.23
KLcys pep-4³ 4 183 204 266 þ 8 1.45 48.5 þ 0.49
KLLcys pep-3³ 3 140 295 206 þ 9 1.47 44.5 þ 0.46
KLLcys pep-4³ 4 186 984 286 þ 6 1.53 49.7 þ 0.55
cysLKL HBVS 2 92 350 117 þ 2 1.27 36.9 þ 0.15
cysLKL DPDPB 2 92 380 118 þ 2 1.28 37.0 þ 0.15
aMW calculated from the amino acid sequence of the protein.
bApparent MW obtained from gel ¢ltration chromatography.
cStokes radius extracted from gel ¢ltration data as described [26].
dCalculated values from the DR1-Ha crystallographic structure [24].
CHBIOL 18 1-9-00 Cyaan Magenta Geel Zwart
688 Chemistry & Biology 2000, Vol 7 No 9
length and chemistry, provides a £exible system in which
oligomers of varying orientation and topological constraints
can be created. We exploited these characteristics to pro-
duce a series of dimeric MHC-peptide complexes that are
connected through the K subunit or L subunit, by short or
long cross-links. Eight topologically distinct MHC-peptide
dimers were constructed, using direct disul¢de bonds (S^S)
or the peptide-based cross-linker (pep-2) to link MHC-
peptide complexes carrying cysteine residues introduced
before (cysKL, KLcys) or after (cysLKL, KLLcys) the connect-
ing peptide region, with cross-links between the K (cysKL,
cysLKL) or L (KLcys, KLLcys) subunits. The puri¢ed MHC-
peptide dimers exhibited the correct covalent cross-links
and the presence of tightly bound peptide antigen, as an-
alyzed by SDS^PAGE (not shown), and gel ¢ltration elu-
tion pro¢les consistent with those expected for MHC-pep-
tide dimers (Figure 6).
Within this set of MHC-peptide dimers, apparent MW
generally were larger for oligomers carrying the connecting
peptide regions as compared to those without, and larger
for oligomers linked by a peptide-based cross-linker as
compared to those linked by a disul¢de bond (Figure 6
and Table 1). Apparent MW for the dimeric complexes
were approximately 20% greater than the actual MW (Ta-
ble 1), consistent with an overall ellipsoidal rather than
spherical shape as expected for concatenated particles.
MHC-peptide monomers exhibited apparent MW similar
to their actual MW, consistent with their roughly spherical
shape, with calculated hydrodynamic radius (Rs) similar
that observed in the crystal structure [26]. An exception
to this general trend is the behavior exhibited by the
MHC-peptide dimers linked through the shorter versions
of the K subunit, cysKL S^S and cysKL pep-2‡. These con-
structions are more compact than the corresponding oligo-
mers linked through the L subunit (Figure 6A), with ap-
parent MW similar to the actual MW, and hydrodynamic
radii (Rs) similar to that of a (KL)2 dimer observed in sev-
eral HLA-DR crystal structures (Table 1) (see Discussion).
MHC-peptide oligomers bind to and trigger activation in
antigen-speci¢c T-cells
We evaluated the utility of the MHC oligomers as immu-
nological reagents by measuring their ability to induce anti-
gen-speci¢c upregulation of the low-af¢nity interleukin-2
(IL-2) receptor CD25, a well-characterized T-cell surface
activation marker [33], using the HLA-DR1-restricted, Ha
peptide-speci¢c human CD4 T-cell clone HA1.7 [34]
(Figure 7). MHC oligomers constructed using commer-
cially available cross-linking reagents to link cysteine resi-
dues on the DRK subunit (cysLKL DPDPB, cysLKL HBVS,
cysLKL S^S and cysLKL TMEA) all induced upregulation of
CD25 in the HA1.7 T-cells, as detected by £ow cytometry
using an allophycocyanin (APC)-labeled monoclonal anti-
body against CD25 (Figure 7A). Relative cell surface ex-
pression levels of CD25 increased by 3^5-fold over the
resting level. Dimers, trimers, and tetramers constructed
using the synthetic £uorescent peptide-based cross-linkers
to link cysteine residues on the DRL subunit (KLLcys pep-
2‡, KLLcys pep-3‡, and KLLcys pep-4‡) also induced T-cell
activation (Figure 7B). We tested MHC dimers linked in
various ways for their ability to activate different T-cell
Figure 6. MHC-peptide oligomers in
various orientations and topological
constraints. Gel ¢ltration chromatography
of puri¢ed MHC-peptide dimers: (A) cysKL
and KLcys, and (B) cysLKL and KLLcys. The
vertical reference line indicates the position
of the midpoint of the dimer peak of cysKL
S^S or cysLKL S^S. The K-coupled dimers
of the short form cysKL S^S and cysKL pep-
2³ appear to be signi¢cantly more compact
than the corresponding dimers coupled
through the L subunit, KLcys S^S and
KLcys pep-2³. For dimers of the long form
cysLKL or KLLcys, any differences in
compactness are much less apparent. The
elution positions of MW standards used to
estimate apparent MW are indicated by
arrows.
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responses. MHC-peptide dimers, linked through either
subunit with a variety of cross-linking reagents, each in-
duced upregulation of CD25, upregulation of the early
activation marker CD69 [35], and downregulation of acti-
vated TCR (CD3) subunits [36] (Figure 7C). In many
cases, the responses were comparable to those induced
by peptide-pulsed antigen-presenting B-cells (B-cells+pep-
tide). Monomeric MHC-peptide complexes did not stimu-
late the HA1.7 T-cells, even at concentrations up to 1.4
WM (Figure 7C). The observed T-cell response to the
oligomers was antigen-speci¢c, as tetramers complexed
with the non-speci¢c endogenous peptide A2 showed no
activation (Figure 7B,C, pep-4‡ A2).
For the oligomers prepared with the £uorescent peptide-
based cross-linkers (KLLcys pep-2‡, KLLcys pep-3‡, KLLcys
pep-4‡), binding to T-cells could be measured directly by
£ow cytometry. Fluorescent chemically cross-linked oligo-
mers could be detected by £ow cytometry as bound to the
CD4 T-cell clone HA1.7 (Figure 8A), while tetramers
carrying the non-speci¢c peptide A2 (pep-4‡ A2) did not
exhibit signi¢cant binding observable above the back-
ground £uorescence (Figure 8A). The ability of the chemi-
cally-de¢ned MHC-peptide oligomers to bind to T-cells
was con¢rmed also in a short-term polyclonal T-cell line
raised from the peripheral blood of a HLA-DR1 individ-
ual. Fluorescent chemically cross-linked oligomers pre-
pared with KLcys MHC-peptide complexes (KLcys pep-2‡,
KLcys pep-3‡, KLcys pep-4‡) bound in an antigen-speci¢c
manner to the polyclonal T-cell line (Figure 8B), as ob-
served with the T-cell clone HA1.7. These results demon-
strate that the oligomeric MHC-peptide reagents could be
useful tools for investigation of ongoing immune responses
in primary T-cells as well as established clones.
Discussion
Oligomeric MHC-peptide complexes as mechanistic
probes and detection reagents
We report a strategy for production of a series of oligomeric
MHC-peptide complexes with varying valency and topo-
logical constraints, by thiol-speci¢c coupling through an
introduced cysteine residue at the C-terminus of the K
subunit or L subunit of the human class II protein HLA-
DR1. We coupled these cysteine-modi¢ed complexes us-
ing direct disul¢de bonds, commercially available cross-
linking reagents, or a novel series of £uorescently labeled,
Figure 7. MHC-peptide oligomers induce activation of the antigen-
speci¢c T-cell clone HA1.7. (A,B) Upregulation of the IL-2
receptor (CD25) by (A) cysLKL oligomers coupled through
commercially available cross-linking reagents and (B) KLLcys
oligomers linked with peptide-based cross-linkers. Dotted pro¢les
show basal surface expression and solid pro¢les activated levels
of CD25 detected by £ow cytometry after 27 h. The activation is
antigen-speci¢c, as tetramers complexed with the endogenous
peptide (pep-4³ A2) do not induce activation. The mean
£uorescence intensity for stimulated cells is shown in each panel,
with the non-stimulated control value in parentheses. Oligomer
concentrations: cysLKL DPDPB (1.1 WM); cysLKL HBVS (1.1 WM);
cysLKL S^S (1.1 WM); cysLKL TMEA (185 nM); KLLcys pep-2³ (350
nM); KLLcys pep-3³ (460 nM); KLLcys pep-4³ (280 nM); and cysLKL
pep-4³ A2 (280 nM). (C) MHC-peptide dimers (1.1 WM), linked
with a variety of cross-linking reagents through the K subunit or
L subunit, are able to trigger T-cell activation in the HA1.7 T-cell
clone as measured by upregulation of CD69 (shaded bars, 12 h),
upregulation of CD25 (IL-2R) (solid bars, 27 h), or downregulation
of activated CD3 (TCR) (open bars, 27 h). Activation is reported
as the fold difference in levels of cell surface expression,
calculated as the ratio of mean £uorescence intensity for
stimulated versus non-stimulated cells. Antigen-presenting cells
pulsed with 1 WM Ha peptide (B-cells+peptide) induce comparable
levels of expression of cell surface markers. Monomeric MHC-
peptide complexes (1.4 WM) did not stimulate activation in any of
the assays tested.
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peptide-based cross-linkers. Previous approaches to the
production of MHC-peptide oligomers include antibody-
mediated oligomerization of MHC-peptide complexes
[22], formation of chimeric immunoglobulins as fusions of
Fc domains with MHC K and L subunits [20,21], and in-
corporation of a target sequence for enzymatic biotinylation
with subsequent oligomerization by streptavidin [23,37^
39]. In all of these cases, the relative £exibility and orien-
tation of monomer units within the oligomer, as well as the
overall oligomer valency, clearly are constrained by the
antibody or streptavidin component of the oligomer. Both
antibody molecules [40] and streptavidin [41] can have
undesired binding to speci¢c receptors on the surface of
mammalian cells. Additionally, most of these reagents can-
not be prepared in homogenous forms free from contami-
nation with larger and smaller oligomers. Fluorescent label-
ing of these compounds can further alter their binding
properties or oligomeric state. In contrast, our chemical
oligomerization approach allows speci¢c cross-linking any-
where in the protein at the introduced cysteine residue,
the cross-linkers can be made in a variety of well-charac-
terized lengths and topological constraints without the
need for a macromolecular linker protein, direct incorpora-
tion of a £uorescent probe into the cross-linker facilitates
measurement of oligomer binding to cell surfaces, and
oligomers of various sizes and topological constraints all
can be prepared in essentially homogenous form.
MHC-peptide dimers trigger T-cell activation
T-cells are activated in vivo by encounter with an antigen-
presenting cell carrying appropriate complexes of surface
MHC protein and peptide antigen. It has been widely
recognized that arti¢cial clustering of TCR components
can also induce T-cell activation processes [7,42^44]. The
valency of TCRs in the activating cluster has been the
focus of much current investigation into the basic molec-
ular mechanisms that underlie immune functions. MHC-
peptide complexes incorporated into planar bilayers [43] or
soluble antigen arrays [44] have been used to investigate
the effects of varying antigen density on T-cell activation.
These studies de¢ned a threshold antigen density required
for activation, but could not provide de¢nitive insight into
the molecular mechanism or nature of the activating spe-
cies. Extracellular antibody-induced cross-linking of TCR
complexes [45], or of chimeras carrying TCR cytoplasmic
domains [46^48] has been shown to mimic T-cell activation
processes induced by antigen-presenting cells, suggesting
that receptor dimerization or aggregation might be neces-
sary for T-cell activation. In several studies, soluble MHC-
peptide multimers have been used to probe the molecular
requirements for T-cell activation. Dimeric MHC-peptide
complexes produced through antibody-mediated oligomer-
ization [22], or fusion of MHC extracellular domains with
antibody Fc portions [19^21], have been shown to induce a
variety of T-cell activation or differentiation processes, pro-
viding evidence that MHC dimers could be suf¢cient for
activation. In contrast, a series of streptavidin-based MHC
oligomers constructed using biotinylated MHC monomers
argued that trimeric complexes were required for ef¢cient
T-cell activation [23].
In our system, every MHC-peptide oligomer tested was
able to induce T-cell activation processes. Dimers linked
through the K or L subunits, with or without the £exible
‘connecting peptide’ regions, and linked through a variety
of coupling chemistries and linker lengths, each was able
to activate T-cells in an antigen-speci¢c manner as judged
by upregulation of cell surface activation markers and
downregulation of activated TCR receptor subunits. In
all, 12 different MHC-peptide dimers (including those pre-
pared by commercially available and novel peptide-based
cross-linkers) were shown to induce a variety of T-cell
activation markers, demonstrating that dimers are suf¢cient
to stimulate activation processes in T-cells. In the physio-
logical context, larger-order clustering of TCR and involve-
ment of other cell surface proteins may contribute to the
Figure 8. MHC-peptide oligomers exhibit antigen-speci¢c binding
to T-cells. Direct binding of (A) KLLcys oligomers to HA1.7 (5 h
incubation), and (B) KLcys oligomers to a short-term polyclonal
T-cell line (12 h incubation) detected with £uorescein labels
incorporated into the cross-linking reagents. Fluorescence of
bound £uorescein oligomer is expressed in each panel (solid
lines), with the background £uorescence of untreated T-cells
indicated in parentheses (dotted lines). MHC oligomers carrying
the Ha peptide bound speci¢cally to the T-cells, whereas
tetramers or trimers carrying the non-speci¢c peptide (pep-4³ A2;
pep-3³ A2) exhibited little or no binding. Concentrations for the
KLLcys oligomers are as per Figure 7 or: KLcys pep-2³ (3.3 WM);
KLcys pep-3³ (1.8 WM); KLcys pep-4³ (1.1 WM); and KLcys pep-3³
A2 (1.5 WM).
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overall cellular activation program [60,61]. The differential
effects of the topologically distinct dimers on T-cell acti-
vation remain to be investigated in detail. In another study
using these oligomeric MHC-peptide complexes, the dose-
dependence of activation by monomers, dimers, trimers,
and tetramers was investigated [32]. Tetramers bound bet-
ter than trimers, and trimers better than dimers, but all
oligomers activated equivalently on the basis of MHC mol-
ecules bound.
X-ray crystallographic analyses of several class II MHC-
peptide complexes have revealed a conserved non-crystal-
lographic dimer of KL heterodimers [49]. Since this discov-
ery, there has been much speculation about the existence
and functional role of these ‘superdimers’ or ‘dimer of
dimers’ in mimicking an activating oligomeric species
that forms transiently at the interface between antigen-pre-
senting cells and T-cells [49^52]. Direct con¢rmation or
contradiction of this hypothesis has proven to be dif¢cult,
but some evidence has been presented in support of the
existence of these MHC-peptide ‘superdimers’ on the sur-
face of living cells [53^55]. The crystallographic MHC-
peptide dimer has a compact, spherical shape, with fric-
tional coef¢cient = 1.0 and calculated hydrodynamic radius
(Rs) = 34.2 Aî (Table 1). In this dimer, the termini of the K
subunits are substantially closer than those of the L subunit
termini (13 versus 39 Aî ). In our series of topologically
varied dimeric MHC-peptide complexes, dimers linked
through shorter K subunits (cysKL S^S and cysKL pep-2‡)
exhibited substantially more compact conformations than
the other dimers, with hydrodynamic radius similar to that
calculated for the crystallographic dimer (Table 1). We hy-
pothesize that these dimers may preferentially assemble
into the close-packed MHC arrangement observed in the
crystal structures. The MHC-peptide complexes and cross-
linking strategy described herein will be useful in evaluat-
ing the physiological relevance of the crystallographic
dimer, and in determining the effect of MHC orientation
on T-cell activation.
Binding af¢nity and receptor rearrangement
Theoretically, the free energy of binding for an oligomer
should equal the sum of (1) a favorable free energy re£ect-
ing the binding of each monomer unit, (2) a favorable
entropic factor resulting from fewer rotational and trans-
lation degrees of freedom lost for binding an additional
monomer in an already bound oligomer, and (3) an unfav-
orable term re£ecting strain or distortion in the oligomer or
its receptor required to achieve the bound state [56]. For
example, for a £exible divalent ligand binding to a multi-
valent cell surface receptor, the free energy of binding
should be greater than the sum of contributions of individ-
ual monomeric components, because once the oligomer has
attached itself to a cell by one monomer, it will undergo a
smaller entropy loss by binding through the second mono-
mer [57]. These effects were demonstrated in the vanco-
mycin system where a rigid trimeric ligand was designed to
bind without distortion to a receptor pre-existing as a
trimer [58]. Here, the binding af¢nity of the trimeric ligand
(KdV1036 M) was approximately the cube of that of a
monomeric ligand (KdV10317 M). The trimer free energy
of binding (V322 kcal/mol) was then approximately the
sum of the three monomer contributions (V38 kcal/mol),
indicating that the ‘strain or distortion’ term was small,
consistent with the prearranged ligand structure. In con-
trast, in the characterization of the binding of divalent anti-
body or monovalent FabP fragments to non-prearranged
MHC class I molecules on a cell surface [59], the af¢nity
of the dimer (KdV1037 M) was found to be tighter than
that of the monomer (KdV1039 M) only by a factor of 50,
corresponding to a dimer free energy of binding substan-
tially lower than the sum of monomer contributions. For a
case of streptavidin-coupled class II MHC oligomers [23],
the af¢nity of a tetramer binding to immobilized mono-
meric TCR was estimated to be only V170 times greater
than that of a MHC monomer. Again, the relatively small
af¢nity increase for the MHC monomer relative to the
multivalent MHC tetramer is consistent with the lack of
prearrangement in the dextran-immobilized TCR used in
the plasmon resonance experiment.
In the case of our MHC-peptide oligomer series binding to
T-cell surfaces, the relative binding af¢nity varied mono-
tonically with oligomer size in a log-linear dependence
(Figure 5B). The apparent free energy increment gained
by adding a second, third, or fourth component into the
oligomer was approximately 0.8 kcal/mol, substantially less
than the apparent binding free energy for the monomer,
estimated to have a lower limit of approximately 37.7 kcal/
mol (see Materials and methods). This indicates that MHC
oligomer binding to T-cells induces strain or distortion in
either the oligomers or T-cell membrane. As the MHC
components in our oligomers would be expected to be
fairly £exible, the strain could be due to rearrangements
in the T-cell membrane necessary to cluster receptors in an
arrangement suitable for oligomeric engagement. In sup-
port of this idea, binding of MHC tetramers is not ob-
served at 4‡C, a temperature at which membrane rear-
rangements are blocked, although this observation may
re£ect a block in TCR internalization at low temperature
(T. Cameron and L. Stern, unpublished results). TCRs as
well as other components involved in interactions with an
antigen-presenting cell are known to relocalize speci¢cally
to the membrane interface during the overall cell^cell in-
teraction process, but the stoichiometry of these colocal-
ized clusters is not known [60,61]. Whether TCRs exist as
preformed dimers in the cell membrane or dimerize upon
engagement with MHC is an outstanding question in T-
cell biology [10,11,32,62]. The relatively small free energy
increment observed with our oligomers and the similarity
of monomer^dimer, dimer^trimer, and trimer^tetramer free
energy increments might argue against pre-existing TCR
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dimers in the membrane, unless binding of MHC oligo-
mers to a pre-existing TCR dimer causes a gross receptor
rearrangement that results in substantial energy loss. An
oligomer series with linkers of varying £exibility should
be examined to address this issue in a de¢nitive manner.
Signi¢cance
Molecular details are not known for the activation of T-
cells by MHC-peptide complexes binding to surface
TCRs, and few tools are available to study these processes.
We prepared chemically-de¢ned dimers, trimers, and tet-
ramers of class II MHC-peptide complexes with varying
intermolecular spacing and orientation, through cysteine
residues incorporated into the MHC protein and thiol-spe-
ci¢c cross-linking reagents. Dimerization of TCR compo-
nents was suf¢cient to trigger T-cell activation, as demon-
strated by induction of T-cell processes with a diverse
variety of cross-linked MHC-peptide dimers. Relative
binding af¢nities within a homologous series of MHC
monomer, dimer, trimer, and, tetramer complexes sug-
gested that TCRs may need to rearrange in the membrane
plane concurrent with oligomeric binding of MHC-peptide
complexes. The capability to systematically vary oligomer
size and intermolecular orientation, and to measure oligo-
mer binding concurrent with activation events by £ow cy-
tometry, are useful tools for probing the molecular mecha-
nism of T-cell activation. This type of approach could have
widespread applications in other areas of protein biochem-
istry and signal transduction, as well as in developing gen-
eral mechanistic probes of receptor^ligand interactions.
Materials and methods
Cysteine residues incorporated in HLA-DR1
Genes encoding the extracellular regions of the K (HLA-DRA1*0101,
SwissProt: P01903) or L (HLA-DRB1*0101, P13758) subunits of HLA-
DR1 were modi¢ed by polymerase chain reaction to include Ala-Cys
(GCATGC) sequences immediately before a stop codon and HindIII
site, and were transferred to Escherichia coli expression plasmids for
T7-mediated expression as described [16]. For the shorter constructions
cysK and Lcys, the cysteine was introduced immediately after the last
residue of the lower immunoglobulin domain AlaK182 or AlaL190. For
the longer constructions cysLK and LLcys, Ala-Cys sequences were intro-
duced after the `connecting peptide' regions K183^192 (PSPLPETTEN)
or L191^198 (RSESAQSK), immediately before the predicted trans-
membrane domains.
Preparation of MHC-peptide complexes
HLA-DR K and L subunits were expressed in E. coli BL21(DE3)pLysS
cells as insoluble inclusion bodies, solubilized in 8 M urea, and puri¢ed
as previously described [16]. Soluble MHC-peptide complexes were
produced by in vitro folding of denatured K and L subunits of HLA-
DR1 in the presence of peptide, by dilution of the denaturant under
redox-controlled conditions [16]. Antigenic peptide Ha[306^318]
(PKYVKQNTLKLAT), derived from in£uenza virus hemagglutinin [63],
and control endogenous peptide A2[103^117] (VGSDWRFLRGYH-
QYA), derived from the class I MHC HLA-A2 [64], were synthesized
using FMOC chemistry, puri¢ed by reverse phase high performance
liquid chromatography (HPLC), and veri¢ed by matrix-assisted laser de-
sorption/ionization mass spectrometry (MALDI-TOF). MHC-peptide com-
plexes carrying C-terminal cysteine residues could not be cross-linked
ef¢ciently after isolation using the standard refolding/puri¢cation protocol
[16], apparently due to reversible modi¢cation of the introduced thiol,
and therefore were puri¢ed in the presence of 5 mM dithiothreitol which
was removed immediately prior to cross-linking.
Thiol assays
The availability of unmodi¢ed, reactive sulfhydryl residues was deter-
mined by treatment of puri¢ed cysteine-modi¢ed MHC proteins with
diethylamino-3-(4-maleimidylphenyl)-4-methylcoumarin (Molecular
Probes), a sensitive, thiol-speci¢c, £uorescent probe. The amount of
free thiol was quantitated by comparison of £uorescence maxima at
469 nm with a standard curve using L-mercaptoethanol. The presence
of reactive sulfhydryl residues was also monitored by dimerization of the
cysteine-modi¢ed MHC-peptide complexes through oxidation mediated
by copper phenanthroline (see below). The amount of reactive thiol was
quantitated by comparison of the resultant MHC-peptide dimer and
monomer peaks on a Superdex 200 gel ¢ltration column (Pharmacia).
Oligomerization using commercially available cross-linking
reagents
Chemical cross-links were made between the long version of the K
subunit of the cysteine-modi¢ed HLA-DR1 peptide complexes (cysLKL)
and thiol-reactive groups on commercially available cross-linking re-
agents. To prepare dimers of DPDPB (Pierce) or HBVS (Pierce), and
trimers of TMEA (Pierce), a 500 WM stock solution of cross-linker was
prepared in dimethyl sulfoxide and added in small batches over 4 h to
MHC-peptide (10^30 WM) in phosphate-buffered saline (PBS; 0.01 M
KH2PO4, 0.1 M Na2HPO4, 1.37 M NaCl, 0.027 M KCl (pH 7.4)), with
1 mM EDTA in a ¢nal molar ratio of 1:2 cross-linker:MHC for dimers and
1:3 cross-linker:MHC for trimers. Cross-links were made through direct
disul¢de bonds between the introduced thiols by addition of 0.25 mM
CuSO4 and 1.3 mM 1,10-phenanthroline (Sigma-Aldrich) to MHC-pep-
tide complexes in 50 mM HEPES (pH 8.0) [31]. The extent of cross-
linking in reaction mixtures was determined by SDS^PAGE (12.5%) and
quantitated with gel ¢ltration chromatography (Superdex 200, Pharma-
cia) by integrating the peak areas. Cross-linked MHC-peptide com-
plexes were puri¢ed by gel ¢ltration on Superdex 200 (Pharmacia),
and integrity of disul¢de bonds and bound peptide was measured by
SDS^PAGE (12.5%, non-reduced vs. reduced and non-boiled vs. boiled
samples, respectively).
Synthesis of novel peptide-based cross-linking reagents
Peptides were synthesized by FMOC chemistry on a solid phase pep-
tide synthesizer, and capped at their N-termini by reaction with £uores-
cein isothiocyanate. TentaGel S RAM FMOC resin (Advanced Chem-
Tech) was used to give a C-terminal amide upon cleavage. L-Alanine
was used as the N-terminal amino acid to prevent thiazolidone formation
and release of £uorescein during peptide deprotection. Peptides were
cleaved from the resin and side-chains were deprotected with 8% tri-
£uoroacetic acid, 2% triisopropylsilane, 5% dithiothreitol, and the ¢nal
product was recovered by ether precipitation. Peptides were puri¢ed by
reverse phase HPLC using an acetonitrile gradient in 0.1% tri£uoroace-
tic acid and a C4 or C18 column (Vydac) and veri¢ed using MALDI-TOF.
To introduce the thiol-speci¢c maleimide group, puri¢ed peptides (2^5
mg) were reacted through the lysine O-amino group with either N-
[O-maleimidocaproyloxy] succinimide ester (Pierce) or succinimidyl-4-
[N-maleimidomethyl]-cyclohexane-1-carboxy-[6-amidocaproate] (Pierce),
by dissolving 5-fold molar excess reagent in N,N-dimethylformamide
and adding it to peptide in 10 mM Na-phosphate buffer (pH 7), 150
mM NaCl [65]. After 1.5 h at room temperature, the modi¢ed peptide
was puri¢ed by reverse phase HPLC on a C18 column (Vydac). Approx-
imate yields of fully modi¢ed peptide were 60% for the dimeric cross-
linker and 40% for the trimeric and tetrameric cross-linker. The presence
of the appropriate number of maleimide functional groups was con¢rmed
by MALDI-TOF.
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Oligomerization using synthetic cross-linking reagents
Chemical cross-links were made through the introduced sulfhydryl on
cysteine-modi¢ed HLA-DR1 and thiol-reactive maleimide groups on the
synthetic peptide-based cross-linking reagents. Cross-linker was added
in small batches to puri¢ed MHC-peptide complex in 10 mM Na-phos-
phate (pH 7), 150 mM NaCl, 5 mM EDTA over approximately 5 h at
room temperature, to a ¢nal MHC:cross-linker ratio of 2:1 for dimers, 3:1
for trimers, and 4:1 for tetramers. Extent of cross-linking was measured
by SDS^PAGE (10%) and gel ¢ltration chromatography as discussed
above. Cross-linked MHC-peptide complexes were isolated by gel ¢ltra-
tion using two Superdex 200 HR 10/30 FPLC columns (Pharmacia) in
series. Purity was determined by SDS^PAGE (10%).
Hydrodynamic studies of MHC-peptide dimers
MW of MHC-peptide complexes were calculated using the amino acid
sequences of protein, peptide, and cross-linkers. Apparent MW (MWapp)
of the MHC-peptide dimers were determined from elution volumes ob-
tained by gel ¢ltration chromatography on two Superdex 200 HR 10/30
columns (Pharmacia). Values were calculated by linear regression using
a calibration curve obtained from the elution volumes of known MW
standards: thyroglobulin (670 kDa), Q-globulin (158 kDa), ovalbumin
(44 kDa), and myoglobin (17 kDa) (Bio-Rad). Con¢dence intervals
( þc) reported in Table 1 re£ect the standard deviation from the mean
elution volume of replicate samples from separate experiments. The
hydrated volumes (not shown) and the Stokes radii (Rs) of the HLA-
DR1-Ha dimers, trimers, and tetramers were derived from the MWapp
values as previously described [26], using a frictional coef¢cient of 1.0
as calculated for the structural dimensions of the HLA-DR1-Ha crystallo-
graphic dimer [24]. The HLA-DR1-Ha monomer has a frictional coef¢-
cient of 1.044 [26].
T-cell clones
The human CD4 T-cell clone HA1.7 [34] was cultured in RPMI (Gibco)
containing 5% human serum (Sigma) and 5% fetal bovine serum (Sig-
ma), and was stimulated every 2 weeks with 120 IU/ml IL-2 (Intergen)
and an irradiated mixture of peripheral blood lymphocytes and EBV1.24,
a DR1 B-cell line, pulsed with 1 WM Ha peptide. The polyclonal T-cell
line was raised from the peripheral blood of a HLA-DR1 individual by in
vitro stimulation with antigenic peptide and cultured as above for HA1.7.
T-cells were rested a minimum of 7 days after stimulation before use in
activation assays and binding experiments.
T-cell activation assays
For activation assays, MHC-peptide oligomers were added to 7.5U104
T-cells in complete medium in round bottom 96-well plates. In some
assays, T-cells were added to 5U104 B-cells (EBV1.24) that had
been pre-pulsed with 1 WM Ha peptide for 2 h at 37³C. After the indi-
cated time at 37³C and 5% CO2, cells were placed on ice and incubated
with £uorescent monoclonal antibodies: APC-labeled anti-CD25 or anti-
CD69 (M-A251 or FN50, Pharmingen), or phycoerythrin-labeled anti-
CD3 (UCHT-1, Sigma). After 1 h at 4³C, cells were washed with PBS
containing 1% fetal bovine serum and 0.1% sodium azide, and analyzed
by £ow cytometry. Fluorescence data were obtained with a Becton-Dick-
inson FACS Calibur £ow cytometer and analyzed using Cell Quest soft-
ware. Some experiment to experiment variation in maximal activation
levels was observed, therefore quantitative comparisons were made
only for samples analyzed in the same experiment.
Oligomer binding assays
For the direct binding assay, levels of cell-associated £uorescence after
oligomer incubation and wash were measured by £ow cytometry using
the £uorescein labels incorporated into the synthetic cross-linkers. MHC-
peptide oligomers were added to T-cells as above and incubated for the
indicated time at 37³C, 5% CO2. Cells were placed on ice and washed
with PBS containing 1% fetal bovine serum and 0.1% sodium azide, and
analyzed by £ow cytometry. For the competitive binding assay, phycoer-
ythrin-labeled, streptavidin-coupled MHC tetramer (SA-PE) [32] was
used as a probe, with competition by unlabeled MHC-peptide oligomers.
These SA-PE tetramers exhibit a strong £uorescence from the R-phy-
coerythrin conjugate, and bind to T-cells in an antigen-speci¢c manner
(T. Cameron and L. Stern, unpublished data). Various concentrations of
MHC oligomers or monomers with a constant amount of SA-PE tetramer
(35 nM) were added to 7.5U104 HA1.7 T-cells in 96-well round bottom
plates and incubated for 3 h at 37³C, 5% CO2. Cells were washed as
described above and £uorescence arising from the bound SA-PE tet-
ramer was measured by £ow cytometry. IC50 values were determined as
the concentration of oligomer or monomer required to reduce the level of
SA-PE tetramer £uorescence to one-half its maximum value [32]. IC50
values are reported as oligomer concentrations; for total MHC concen-
tration, the IC50 should be multiplied by the oligomer valency. Error bars
represent replicate measurements from separate experiments. Binding
free energies were estimated using the relationship vG = 2.3RT(log Kd),
with vG =vGmon+nvGoligo, where n = oligomer size, as shown by the
linear plot of IC50 versus n. In this analysis, we assume Kd = IC50.
This assumption will be true if the concentration of phycoerythrin-labeled
streptavidin-cross-linked MHC, [SA-PE], is substantially less than its
binding af¢nity Kd;SAÿPE. If [SA-PE] is substantial, the experimental
IC50 will overestimate the Kd by the factor K= 1/(1+[SA-PE]/Kd;SAÿPE),
and the calculated vGmon will underestimate the true vGmon by the factor
ln K.
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